30 closest matches · ranked by relevance
Pancreatic Mucinous-Cystic Neoplasm
Primary: Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 3; 9 Participants
Pancreatic Cysts
Primary: Prevalence of Pancreatic Cysts During Routine EUS — 46 participants found to have a cyst
Neoplasms, Cystic, Mucinous, and Serous
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 7; 16 participants
Healthy Volunteers
Primary: Total Secreted Fluid Volume as Measured by MR-PFT — 79 mL
Mucinous Pancreatic Cysts
Primary: Number of Participants With the Changing in Cyst Volume — 6; 12; 5; 4 Participants
Pancreatic Cysts
Primary: Sensitivity — 59 percentage of participants
Pancreatic Cystic Lesions
Primary: Volume of Aspirated Cyst Fluid as a Function of Estimated Maximal Volume — 78; 74; 73 percentage of cyst volume aspirated — p=0.84
Pancreatic Cancer
Primary: S-MRCP and S-EUS Concordance
Pancreatic Fistula
Primary: Number of Patients With Pancreatic Fistula — 9; 8 participants
Pancreatic Pseudocysts
Primary: Technical Success of Endoscopic Ultrasound-guided Single-access Pseudocyst Drainage With a Fully Covered Self-expanding Metal Stent ; Anchored With a Double Pigtail…
Von Hippel-Lindau Disease
Primary: Number of Patients With Pancreatic Lesions Defined by Simple Cysts, Microcystic Adenomas, Neuroendocrine Tumors & Other Solid Lesions of the Pancreas Who Had Significant…
Pancreatic Adenocarcinoma
Primary: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort — 99097; 34095 pg/ml — p=<0.001
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Chronic Pancreatitis
Primary: Malabsorption Blood Test: Difference in Mean HA AUC Between Groups: Subjects With CP Compared to Healthy Subjects — 8.3; 17.7 mg*h/dL — p=<0.001
Pancreas Tumor · Pancreatitis
Primary: 60-day ≥ Grade II Complication Rate — 72; 76 Participants — p=0.804
Pancreaticobiliary Reflux
Primary: Amylase and Lipase Values in Gallbladder Bile — 5.5; 181.2; 9.5; 434.8 mg/dl
Injury of Body of Pancreas
Primary: Number of Participants With Biochemical Leak/Grade B Fistula/Grade C Fistula — 25; 16; 3; 5 Participants
Cystic Fibrosis · Exocrine Pancreatic Insufficiency · Pancreatic Diseases
Primary: Number of Patients With Adverse Drug Reaction — 1 participants
Cystic Fibrosis
Primary: Number of Participants Who Fully Completed at Least One ePRO — 133; 196; 130; 194 Participants
Cystic Fibrosis
Primary: Coefficient of Fat Absorption (%) — 88.62; 49.78 Percentage — p=<0.001
Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Primary: Coefficient of Fat Absorption (CFA) — 88.1; 89.5 percentage of fat intake
Colon Cancer · Pancreatic Cancer · Cholangiocarcinoma
Primary: Number of Participants With Disease Recurrence At 1 Year — 2; 0 Participants
Chronic Pancreatitis
Primary: Pain Reduction — 12 Participants — p=0.999
Pancreatic Adenocarcinoma
Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants
Cystic Fibrosis · Pancreatic Exocrine Insufficiency
Primary: Number of Patients With at Least One Treatment Emergent Adverse Event (TEAE) — 9 Participants
Pancreatic Carcinoma
Primary: Number of Serious Pre-operative, Operative and Post-operative Adverse Events to 120 Days Post Randomization or to 30 Days Post Surgery, Whichever Comes Last — 40; 36…
Pancreatic Fistulae
Primary: Decreased Secretions — 1 participants
Pancreatic Adenocarcinoma
Primary: Survival in Patients With Pancreatic Adenocarcinoma According to Tissue microRNA Expression — 8.3 months
Pancreatic Cancer
Primary: Effects of PEGPH20
Pancreas Cancer · Pancreas Disease · Pancreas Adenocarcinoma
Primary: Number of Participants With a Clinically Significant Post-operative Pancreatic Fistula (POPF) — 13 Participants